1 Klinik for Klinisk Fysiologi, Nuklearmedicin og PET, Diagnostisk Center, Rigshospitalet, The Capital Region of Denmark2 Department of Health Sciences, Faculty of Medicine, Lund University, Lund, Sweden3 unknown
Most carcinomas are prone to metastasize despite successful treatment of the primary tumor. One way to address this clinical challenge may be targeted therapy with α-emitting radionuclides such as astatine-211 (211At). Radioimmunotherapy utilizing α-particle emitting radionuclides is considered especially suitable for the treatment of small cell clusters and single cells, although lesions of different sizes may also be present in the patient. The aim of this study was primarily to evaluate the toxicity and secondarily in vivo efficacy of a 211At-labeled monoclonal antibody (mAb) directed against colon carcinoma with tumor diameters of approximately 10 mm.